Search

Your search keyword '"bluebird bio, Inc. -- Product development"' showing total 13 results

Search Constraints

Start Over You searched for: Descriptor "bluebird bio, Inc. -- Product development" Remove constraint Descriptor: "bluebird bio, Inc. -- Product development" Journal m2 presswire Remove constraint Journal: m2 presswire
13 results on '"bluebird bio, Inc. -- Product development"'

Search Results

1. Stem Cell Therapy Market to Register 11.2% CAGR by 2031 Amidst Expanding Pipeline of Clinical Trials

2. Sickle Cell Disease Pipeline Assessment 2024: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, MOA, ROA and Companies by DelveInsight | Bellicum Pharmaceuticals, Novartis, Novo Nordisk, more

3. CAR-T Pipeline Outlook, FDA Approvals, Clinical Trials, and Companies 2024 (Updated)

4. Car T Cell Therapy For Multiple Myeloma Pipeline Drugs Analysis Report: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | CARsgen Therapeutics, Poseida Therapeutics, Juno

5. Sickle Cell Disease Pipeline Report: FDA, EMA, and PMDA Approvals, Treatments, Clinical Trials, and Companies by DelveInsight | Bellicum Pharmaceuticals, Novartis, Novo Nordisk, Vertex Pharmaceuticals

6. Assessment of RNA Interference Pipeline and Clinical Trials in 2023: FDA Approvals, Therapeutics, and Companies by DelveInsight | Moderna Therapeutics, GenSight Biologics, Pfizer, bluebird bio

7. RNA interference Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Moderna Therapeutics, GenSight Biologics, Pfizer, bluebird bio

8. Sickle Cell Disease Pipeline, Clinical Trials Assessment, FDA Approvals 2023 (Updated)

9. TCR Therapy Pipeline and Clinical Trials Pipeline Analysis 2023 (Updated): 25+ Companies are working to improve the Treatment of Space | Immatics N.V., Anocca AB, Gritstone, LION TCR, MediGene AG

10. Sickle Cell Disease Pipeline Drugs Analysis Report 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

11. Gene Therapy Competitive Landscape Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

12. Chimeric Antigen Receptor (CAR) T-Cell Therapy Pipeline Insights, 2023 Updates | Clinical and Non-Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Key Companies

13. Sickle Cell Disease Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Catalog

Books, media, physical & digital resources